684 related articles for article (PubMed ID: 28601342)
1. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.
Rullier E; Rouanet P; Tuech JJ; Valverde A; Lelong B; Rivoire M; Faucheron JL; Jafari M; Portier G; Meunier B; Sileznieff I; Prudhomme M; Marchal F; Pocard M; Pezet D; Rullier A; Vendrely V; Denost Q; Asselineau J; Doussau A
Lancet; 2017 Jul; 390(10093):469-479. PubMed ID: 28601342
[TBL] [Abstract][Full Text] [Related]
2. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial.
Rullier E; Vendrely V; Asselineau J; Rouanet P; Tuech JJ; Valverde A; de Chaisemartin C; Rivoire M; Trilling B; Jafari M; Portier G; Meunier B; Sieleznieff I; Bertrand M; Marchal F; Dubois A; Pocard M; Rullier A; Smith D; Frulio N; Frison E; Denost Q
Lancet Gastroenterol Hepatol; 2020 May; 5(5):465-474. PubMed ID: 32043980
[TBL] [Abstract][Full Text] [Related]
3. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
4. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.
Bach SP; Gilbert A; Brock K; Korsgen S; Geh I; Hill J; Gill T; Hainsworth P; Tutton MG; Khan J; Robinson J; Steward M; Cunningham C; Levy B; Beveridge A; Handley K; Kaur M; Marchevsky N; Magill L; Russell A; Quirke P; West NP; Sebag-Montefiore D;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):92-105. PubMed ID: 33308452
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
6. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
8. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial.
Park JW; Kang SB; Hao J; Lim SB; Choi HS; Kim DW; Chang HJ; Kim DY; Jung KH; Kim TY; Kang GH; Chie EK; Kim SY; Sohn DK; Kim JS; Lee HS; Kim JH; Jeong SY; Oh JH
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):569-577. PubMed ID: 33894918
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial.
Gerard JP; Barbet N; Schiappa R; Magné N; Martel I; Mineur L; Deberne M; Zilli T; Dhadda A; Myint AS;
Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):356-367. PubMed ID: 36801007
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
[TBL] [Abstract][Full Text] [Related]
11. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.
Fujita S; Akasu T; Mizusawa J; Saito N; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Shiozawa M; Yamaguchi T; Moriya Y;
Lancet Oncol; 2012 Jun; 13(6):616-21. PubMed ID: 22591948
[TBL] [Abstract][Full Text] [Related]
12. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Garcia-Aguilar J; Chow OS; Smith DD; Marcet JE; Cataldo PA; Varma MG; Kumar AS; Oommen S; Coutsoftides T; Hunt SR; Stamos MJ; Ternent CA; Herzig DO; Fichera A; Polite BN; Dietz DW; Patil S; Avila K;
Lancet Oncol; 2015 Aug; 16(8):957-66. PubMed ID: 26187751
[TBL] [Abstract][Full Text] [Related]
13. Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial.
Feng Q; Yuan W; Li T; Tang B; Jia B; Zhou Y; Zhang W; Zhao R; Zhang C; Cheng L; Zhang X; Liang F; He G; Wei Y; Xu J;
Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):991-1004. PubMed ID: 36087608
[TBL] [Abstract][Full Text] [Related]
14. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer.
Madbouly KM; Hussein AM; Abdelzaher E
Am J Surg; 2014 Sep; 208(3):332-41. PubMed ID: 24581995
[TBL] [Abstract][Full Text] [Related]
15. Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).
Serra-Aracil X; Pericay C; Badia-Closa J; Golda T; Biondo S; Hernández P; Targarona E; Borda-Arrizabalaga N; Reina A; Delgado S; Vallribera F; Caro A; Gallego-Plazas J; Pascual M; Álvarez-Laso C; Guadalajara-Labajo HG; Mora-Lopez L
Ann Oncol; 2023 Jan; 34(1):78-90. PubMed ID: 36220461
[TBL] [Abstract][Full Text] [Related]
16. Non-inferiority multicenter prospective randomized controlled study of rectal cancer T
Serra-Aracil X; Pericay C; Golda T; Mora L; Targarona E; Delgado S; Reina A; Vallribera F; Enriquez-Navascues JM; Serra-Pla S; Garcia-Pacheco JC;
Int J Colorectal Dis; 2018 Feb; 33(2):241-249. PubMed ID: 29234923
[TBL] [Abstract][Full Text] [Related]
17. Individualizing surgical treatment based on tumour response following neoadjuvant therapy in T4 primary rectal cancer.
Denost Q; Kontovounisios C; Rasheed S; Chevalier R; Brasio R; Capdepont M; Rullier E; Tekkis PP
Eur J Surg Oncol; 2017 Jan; 43(1):92-99. PubMed ID: 27717529
[TBL] [Abstract][Full Text] [Related]
18. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
[TBL] [Abstract][Full Text] [Related]
19. [Outcome of watch and wait strategy or organ preservation for rectal cancer following neoadjuvant chemoradiotherapy: report of 35 cases from a single cancer center].
Wu A; Wang L; Du C; Peng Y; Yao Y; Zhao J; Zhan T; Cai Y; Li Y; Sun Y; Ji J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):417-424. PubMed ID: 28440523
[TBL] [Abstract][Full Text] [Related]
20. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
